302 related articles for article (PubMed ID: 23540598)
1. Whole-organism high-throughput screening against Trypanosoma brucei brucei.
Jones AJ; Avery VM
Expert Opin Drug Discov; 2013 May; 8(5):495-507. PubMed ID: 23540598
[TBL] [Abstract][Full Text] [Related]
2. Drug discovery for human African trypanosomiasis: identification of novel scaffolds by the newly developed HTS SYBR Green assay for Trypanosoma brucei.
Faria J; Moraes CB; Song R; Pascoalino BS; Lee N; Siqueira-Neto JL; Cruz DJ; Parkinson T; Ioset JR; Cordeiro-da-Silva A; Freitas-Junior LH
J Biomol Screen; 2015 Jan; 20(1):70-81. PubMed ID: 25342146
[TBL] [Abstract][Full Text] [Related]
3. 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
Ferrins L; Rahmani R; Sykes ML; Jones AJ; Avery VM; Teston E; Almohaywi B; Yin J; Smith J; Hyland C; White KL; Ryan E; Campbell M; Charman SA; Kaiser M; Baell JB
Eur J Med Chem; 2013 Aug; 66():450-65. PubMed ID: 23831695
[TBL] [Abstract][Full Text] [Related]
4. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei.
Mackey ZB; Baca AM; Mallari JP; Apsel B; Shelat A; Hansell EJ; Chiang PK; Wolff B; Guy KR; Williams J; McKerrow JH
Chem Biol Drug Des; 2006 May; 67(5):355-63. PubMed ID: 16784460
[TBL] [Abstract][Full Text] [Related]
5. Identification and Characterization of FTY720 for the Treatment of Human African Trypanosomiasis.
Jones AJ; Kaiser M; Avery VM
Antimicrob Agents Chemother; 2015 Dec; 60(3):1859-61. PubMed ID: 26666915
[TBL] [Abstract][Full Text] [Related]
6. Identification of compounds with anti-proliferative activity against Trypanosoma brucei brucei strain 427 by a whole cell viability based HTS campaign.
Sykes ML; Baell JB; Kaiser M; Chatelain E; Moawad SR; Ganame D; Ioset JR; Avery VM
PLoS Negl Trop Dis; 2012; 6(11):e1896. PubMed ID: 23209849
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.
Urbaniak MD; Tabudravu JN; Msaki A; Matera KM; Brenk R; Jaspars M; Ferguson MA
Bioorg Med Chem Lett; 2006 Nov; 16(22):5744-7. PubMed ID: 16962325
[TBL] [Abstract][Full Text] [Related]
8. Sleeping sickness pathogen (Trypanosoma brucei) and natural products: therapeutic targets and screening systems.
Hannaert V
Planta Med; 2011 Apr; 77(6):586-97. PubMed ID: 20945274
[TBL] [Abstract][Full Text] [Related]
9. Parasite-based screening and proteome profiling reveal orlistat, an FDA-approved drug, as a potential anti Trypanosoma brucei agent.
Yang PY; Wang M; Liu K; Ngai MH; Sheriff O; Lear MJ; Sze SK; He CY; Yao SQ
Chemistry; 2012 Jul; 18(27):8403-13. PubMed ID: 22674877
[TBL] [Abstract][Full Text] [Related]
10. Development of drug resistance in Trypanosoma brucei rhodesiense and Trypanosoma brucei gambiense. Treatment of human African trypanosomiasis with natural products (Review).
Gehrig S; Efferth T
Int J Mol Med; 2008 Oct; 22(4):411-9. PubMed ID: 18813846
[TBL] [Abstract][Full Text] [Related]
11. Future treatment options for human African trypanosomiasis.
Jones AJ; Avery VM
Expert Rev Anti Infect Ther; 2015; 13(12):1429-32. PubMed ID: 26414688
[TBL] [Abstract][Full Text] [Related]
12. In vitro trypanocidal activity of the anti-helminthic drug niclosamide.
Merschjohann K; Steverding D
Exp Parasitol; 2008 Apr; 118(4):637-40. PubMed ID: 18226810
[TBL] [Abstract][Full Text] [Related]
13. 6-Arylpyrazine-2-carboxamides: A New Core for Trypanosoma brucei Inhibitors.
Rahmani R; Ban K; Jones AJ; Ferrins L; Ganame D; Sykes ML; Avery VM; White KL; Ryan E; Kaiser M; Charman SA; Baell JB
J Med Chem; 2015 Sep; 58(17):6753-65. PubMed ID: 26247439
[TBL] [Abstract][Full Text] [Related]
14. Current chemotherapy of human African trypanosomiasis.
Docampo R; Moreno SN
Parasitol Res; 2003 Jun; 90 Supp 1():S10-3. PubMed ID: 12811544
[TBL] [Abstract][Full Text] [Related]
15. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug.
Huang TL; Bacchi CJ; Kode NR; Zhang Q; Wang G; Yartlet N; Rattendi D; Londono I; Mazumder L; Vanden Eynde JJ; Mayence A; Donkor IO
Int J Antimicrob Agents; 2007 Dec; 30(6):555-61. PubMed ID: 17920820
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy against human African trypanosomiasis: is there a road to success?
Burri C
Parasitology; 2010 Dec; 137(14):1987-94. PubMed ID: 20961469
[TBL] [Abstract][Full Text] [Related]
17. Discovery and antiparasitic activity of AZ960 as a Trypanosoma brucei ERK8 inhibitor.
Valenciano AL; Ramsey AC; Santos WL; Mackey ZB
Bioorg Med Chem; 2016 Oct; 24(19):4647-4651. PubMed ID: 27519462
[TBL] [Abstract][Full Text] [Related]
18. Folates in Trypanosoma brucei: Achievements and Opportunities.
Cullia G; Tamborini L; Conti P; De Micheli C; Pinto A
ChemMedChem; 2018 Oct; 13(20):2150-2158. PubMed ID: 30152195
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents.
Yang PY; Wang M; Li L; Wu H; He CY; Yao SQ
Chemistry; 2012 May; 18(21):6528-41. PubMed ID: 22488888
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationships of new quinolone-type molecules against Trypanosoma brucei.
Hiltensperger G; Jones NG; Niedermeier S; Stich A; Kaiser M; Jung J; Puhl S; Damme A; Braunschweig H; Meinel L; Engstler M; Holzgrabe U
J Med Chem; 2012 Mar; 55(6):2538-48. PubMed ID: 22376072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
